Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 6/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | LIG1 | P18858 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871784 | 0.83 | F2 (0.52) | CA2LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL21844839 | 0.82 | CA2 (0.49) | CA2LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL2006698 | 0.81 | NPSR1 (0.74) | CA2LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL15851416 | 0.81 | LMNA (0.48) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL9229855 | 0.80 | CA2 (0.55) | CA2LMNACA12CA1CA9 | |
| SCHEMBL322182 | 0.79 | DAO (0.52) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL16237287 | 0.79 | DAO (0.52) | LMNAPPARGNCOA2NCOA1NPSR1 | |
| SCHEMBL27863128 | 0.78 | LMNA (0.44) | CA2LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL7855061 | 0.77 | CA2 (0.42) | CA2LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL2231037 | 0.77 | HDAC6 (0.51) | CA2CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| CN-114206335-B | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-4446314-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-3962479-B1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PREC MEDICINES INC (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114206335-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3962479-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227097-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| US-6174883-B1 | ENZYME INHIBITORS OF PROSTAGLANDIN H2 SYNTHASE, 5-LIPOXYGENASE; INHIBITORS OF INTERLEUKIN-1 BIOSYNTHESIS; ANALGESICS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; BONE, CONNECTIVE TISSUE METABOLISM AND SKIN DISORDERS | PFIZER INC. | 2001-01-16 | — | — | US | disclosed |
| US-5919809-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1999-07-06 | — | — | US | disclosed |
| EP-0393936-B1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER (US) | 1995-02-22 | — | — | EP | disclosed |
| US-5300655-A | 2-carboxy-thiophene derivatives | PFIZER INC. (US) | 1994-04-05 | — | — | US | disclosed |
| US-5290802-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5047554-A | 3-substituted-2-oxindole derivatives | PFIZER INC. (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0393936-A1 | 3-substituted-2-oxindole derivatives as antiinflammatory agents | PFIZER INC. (US) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | CA2 624/4885LMNA 1423/4885PPARG 4045/4885 |
| US-20070232583-A1 | Pyridine and pyrimidine derivatives as mGIuR2 antagonists | P2RX2, P2RY2, P2RX1 | CA2 2101/4885LMNA 4514/4885PPARG 1457/4885 |
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | CA2 9/4885LMNA 2986/4885PPARG 2154/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | CA2 1428/4885LMNA 4509/4885PPARG 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.